CCKBR and neoplasm: In vivo, the multitriazolo-peptidomimetics showed a further 1.5-fold increase in tumour uptake and a 2- to 3-fold increase in the tumour-to-kidney ratio in athymic nude mice with CCK2R-positive tumour xenografts compared to mono-triazole compound MGN6.